Kittanning

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have high PD-L1 expression. This Phase III, randomized, double-blind, and global study focuses on participants with stage IV mNSCLC who do not have certain genetic mutations or rearrangements and are eligible for systemic therapy. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle. The study compares these two biological treatments given as monotherapy. Both groups will be monitored over time to assess treatment impact and safety. Throughout the study, participants undergo evaluations including tumor measurements by CT or MRI, performance status assessments, and organ function tests. Researchers will measure overall survival and progression-free survival for up to approximately five years. Tumor samples are collected before treatment for central testing, and participants’ health and treatment responses are closely followed during the trial period.

Researchers are evaluating the effectiveness of four different dehydrated human placental membrane products, also called Cellular, Acellular, Matrix-like Products (CAMPs), combined with standard care compared to standard care alone for treating hard-to-heal diabetic foot ulcers over 12 weeks. This multicenter, randomized clinical trial uses a modified platform design to study multiple skin substitute products, including Revita®, Relese®, Cogenex®, and Enverse®, in a single trial setting. Participants will receive weekly treatments with one of the four CAMP products plus standard care or standard care alone. Standard care includes cleaning, debridement, managing ulcer moisture, and offloading the ulcer area, applied weekly until the ulcer closes or for a maximum of 12 weeks. The study aims to assess and compare how well each treatment supports complete healing of the diabetic foot ulcers. During the trial, participants will attend weekly visits for treatment and monitoring. Researchers will evaluate wound closure rates, measuring the percentage of ulcers that fully close within 1 to 12 weeks. Vascular assessments, imaging, and other evaluations will be used to ensure ulcer suitability and track healing progress. Safety and treatment adherence will be monitored throughout the study period.